Sanofi and partner progress add-on insulin therapy

29 March 2018
sanofi-big-1

French pharma major Sanofi (Euronext: SAN) is a step closer to the European market with its submission for sotagliflozin, an addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes mellitus.

The European Medicines Agency (EMA) has accepted the company’s regulatory submission for the dual inhibitor of SGLT-1 and SGLT-2, proteins that influence how the intestines and kidneys process blood sugar.

It was developed in partnership with Lexicon Pharmaceuticals (Nasdaq: LXRX), with Sanofi paying the Texan biotech firm $300 million on the signing of the 2015 deal, and up to $1.2 billion in milestone payments.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical